ONCORAL PHARMA ApS

CVR 35481214 · Private limited company (ApS) · Active · High risk

ONCORAL PHARMA ApS is a Private limited company (ApS), founded on , based in København K. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 4.5% over the next 12 months, which is 3.2 times the average for Danish companies. 11 annual reports have been published, of which 2 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK -35.5m and a net result of DKK -2.3m.

Bankruptcy risk for ONCORAL PHARMA ApS

4.5%
probability of bankruptcy within 12 months
High risk

3.2 × the average (1.41%) · higher risk than 91% of active Danish companies

Lowest riskHighest risk

Increases the risk

Equity ratio< -50% · bankruptcy rate 19.3%2.2×
Negative equityYes · bankruptcy rate 17.5%2.0×
Equity vs. share capital< 0× · bankruptcy rate 17.3%2.0×
Return on assets< -20% · bankruptcy rate 16.7%1.9×
Time at current address0.5–1 yrs · bankruptcy rate 16.5%1.9×
Moves in the last 2 years1 · bankruptcy rate 12.7%1.4×
Number of CEOs0 · bankruptcy rate 12.7%1.4×
RegionHovedstaden · bankruptcy rate 11.6%1.3×

Reduces the risk

Auditor's statementExtended review · bankruptcy rate 2.9%0.33×
Published annual reports10+ · bankruptcy rate 3.0%0.35×
Age (years)10–20 yrs · bankruptcy rate 3.9%0.45×
Share of late annual reports0.01%–25% · bankruptcy rate 4.5%0.51×
Number of auditors (historical)2 · bankruptcy rate 4.6%0.52×
Auditor registered in CVRYes · bankruptcy rate 4.8%0.55×
Audit opted outNo · bankruptcy rate 4.8%0.55×
Reporting classReporting class B · bankruptcy rate 5.7%0.65×

The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.

Company details

CVR number
35481214
Status
Active
Company type
Private limited company (ApS)
Founded
(13 years)
Address
c/o Jusmedico Advokatanpartsselskab, Amaliegade 6, 2. tv
1256 København K
Municipality
København
Industry
Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Share capital
DKK 146k
Employees
0 (2014)
Auditor
PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB
Audit opted out
No

Warning signs

Annual reports filed late2 of 11
Missing annual reportNo
Negative equityYes
Equity ratio-3,908.2%
Current ratio43%
Moves (last 2 years)1
CEO changes in total1
CEO's previous bankruptcies0
Other companies at the address240
Going-concern uncertaintyNo

Financials and key figures

Financial year202520242023
Gross profitDKK -1.6mDKK -367kDKK -996k
Net profitDKK -2.3mDKK -4.1mDKK -2.7m
EquityDKK -35.5mDKK -33.2mDKK -29.1m
Total assetsDKK 908kDKK 679kDKK 9.5m
CashDKK 783kDKK 500k–
Short-term debtDKK 1.9mDKK 1.5m–
Avg. employees11–

Latest annual report: Reporting class B · auditor's statement: Erklæring om udvidet gennemgang · PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab.

Filed annual reports

Reporting periodPublishedDays after period end
1 Jan 2025 – 31 Dec 2025166
1 Jan 2024 – 31 Dec 2024154
1 Jan 2023 – 31 Dec 2023183
1 Jan 2022 – 31 Dec 2022187 Late
1 Jan 2021 – 31 Dec 2021188 Late
1 Jan 2020 – 31 Dec 2020180
1 Jul 2018 – 30 Jun 2019142
1 Jan 2017 – 30 Jun 2018136
1 Jan 2016 – 31 Dec 2016131
1 Jan 2015 – 31 Dec 2015146
25 Sep 2013 – 31 Dec 2014151

The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.

Management, owners and auditor

RoleNameFromTo
CEOPeter Gudmund Nielsen
BoardJørn Frederik Falch
BoardAnn Vivian Fullerton
BoardPeter Gudmund Nielsen
BoardMette Munch
Owner (100%)Ascelia Pharma ABCurrent
Owner (25%)Styrelsen for Forskning og Uddannelse
Owner (67%)PEBEAN HOLDING ApS
Owner (5%)CAPNOVA A/S
Owner (20%)Styrelsen for Forskning og Uddannelse
Owner (20%)Uddannelses- og Forskningsstyrelsen
AuditorPRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKABCurrent
AuditorPRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB
AuditorKPMG P/S
FounderØSTJYSK INNOVATION A/SCurrent

The CEOs' other companies

Peter Gudmund Nielsen – 4 other companies

Address history (4 moves)

c/o Jusmedico Advokatanpartsselskab, Amaliegade 6, 2. tv, 1256 København K
c/o Jusmedico Advokatanpartsselskab, Teknikerbyen 5, 2., 2830 Virum
c/o Jusmedico Advokatanpartsselskab, Klampenborgvej 248, 1. mf, 2800 Kgs. Lyngby
c/o Jusmedico Advokatanpartsselskab, Kongevejen 371, 2840 Holte
Energivej 42, 2750 Ballerup

Employees per year

Number of employees at ONCORAL PHARMA ApS per year352013: 520132014: 02014

Other companies at the same address

Similar companies in København

Questions and answers about ONCORAL PHARMA ApS

Has ONCORAL PHARMA ApS gone bankrupt?

No, ONCORAL PHARMA ApS is not registered as bankrupt in the CVR register. Its status is: active.

What is the bankruptcy risk of ONCORAL PHARMA ApS?

Our model estimates a bankruptcy risk of 4.5% over the next 12 months (high risk), which is 3.2 times the average for Danish companies.

Who is the auditor of ONCORAL PHARMA ApS?

ONCORAL PHARMA ApS most recently used PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB.

When was ONCORAL PHARMA ApS founded?

ONCORAL PHARMA ApS was founded on 25 September 2013.

What is the equity of ONCORAL PHARMA ApS?

Equity was DKK -35.5m according to the annual report for the period ending 31 December 2025.

Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.